Bohuslav Melichar

5PUBLICATIONS
42CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Mar 02, 2026
Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum.

Ondřej Peterka, Robert Jirásko, Zuzana Dolečková

|Sep 11, 2024
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02.

Ana Oaknin, Jung-Yun Lee, Vicky Makker

|Mar 16, 2024
The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting.

Jindřich Kopecký, Marek Pásek, Radek Lakomý

|Oct 05, 2020
Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.

Martina Spisarová, Bohuslav Melichar, Denisa Vitásková

Pageof 1

Frequent Collaborators

2 joint publications

Iwona Ługowska

2 joint publications

Funda Meric-Bernstam

2 joint publications

Soham Puvvada

2 joint publications

Antonio González-Martín